Przydatność oceny stężenia łańcuchów lekkich neurofilamentów w surowicy w codziennej praktyce klinicznej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2024
Słowa kluczowe:
stwardnienie rozsiane, łańcuchy lekkie neurofilamentów, klinicznie izolowany zespół
##plugins.themes.bootstrap3.article.main##
Abstrakt
Neurofilamenty są składnikami cytoszkieletu, a wzrost ich stężenia w surowicy jest wykładnikiem uszkodzenia neuroaksonalnego. Oznacza to, że są markerem uszkodzenia ośrodkowego układu nerwowego. Ich szczególne znaczenie jest obecnie badane w wielu chorobach neurologicznych, zwłaszcza w stwardnieniu rozsianym, stwardnieniu bocznym zanikowym, czy w urazach mózgu. W stwardnieniu rozsianym stężenie łańcuchów lekkich neurofilamentów w surowicy jest rozpatrywane jako predyktor krótkoterminowej progresji choroby, długoterminowej progresji choroby oraz jako biomarker odpowiedzi na leczenie modyfikujące przebieg choroby. Ponieważ neurofilamenty są markerem tkankowo specyficznym, a wzrost ich stężenia odzwierciedla utratę neuronów w czasie rzeczywistym, wydają się one prostym i użytecznym narzędziem oceny aktywności choroby.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Freedman MS, Gnanapavan S, Booth RA et al.; Consortium of Multiple Sclerosis Centers. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine. 2024; 101: 104970. http://doi.org/10.1016/j.ebiom.2024.104970.
2.Oset M, Domowicz M, Wildner P et al. Predictive value of brain atrophy, serum biomarkers and information processing speed for early disease progression in multiple sclerosis. Front Neurol. 2023; 14: 1223220. http://doi.org/10.3389/fneur.2023.1223220.
3. Abdelhak A, Petermeier F, Benkert P et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 2023; 22(9): 826-33. http://doi.org/10.1016/S1474-4422(23)00210-7.
4. Monreal E, Fernández-Velasco JI, García-Sánchez MI et al. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurol. 2023; 80(4): 397-403. http://doi.org/10.1001/jamaneurol.2023.0010.
5.Arroyo Pereiro P, Muñoz-Vendrell A, León Moreno I et al. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort. J Neurol. 2024; 271(4): 1599-609. .
6. Bar-Or A, Thanei GA, Harp C et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023; 93: 104662. http://doi.org/10.1016/j.ebiom.2023.104662.
7.Fissolo N, Benkert P, Sastre-Garriga J et al. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2024; 95(5): 410-8. http://doi.org/10.1136/jnnp-2023-332251.
8. Williams T, Zetterberg H, Chataway J. Neurofilaments in progressive multiple sclerosis: a systematic review. J Neurol. 2021; 268(9): 3212-22. http://doi.org/10.1007/s00415-020-09917-x.
9. van Dam M, de Jong BA, Willemse EAJ et al. A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort. J Neurol. 2023; 270(8): 3851-61. http://doi.org/10.1007/s00415-023-11676-4.
10. Valentino P, Malucchi S, Bava CI et al. Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients. Mult Scler Relat Disord. 2023; 77: 104893. http://doi.org/10.1016/j.msard.2023.104893.
11. Oh U, Woolbright E, Lehner-Gulotta D et al. Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet. Mult Scler Relat Disord. 2023; 73: 104670. http://doi.org/10.1016/j.msard.2023.104670.
12. Kuhle J, Kappos L, Cross AH et al. Baseline serum neurofilament light levels have prognostic value for on-study MRI activity: Results from ASCLEPIOS trials; P0033. Zaprezentowano podczas kongresu ACTRIMS-ECTRIMS 11–13.09.2020 r.
13. Prado G, Kappos L, Cross AH et al. Ofatumumab Reduces Clinical and Radiological Activity in People With Recently Diagnosed Treatment-Naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels; P9.008. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
14. Leist T, Hauser S, Derfuss T et al. Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With\ Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials; P032. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
15. Cross A, Ziemssen T, Arnold D T et al. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients With Relapsing Multiple Sclerosis: Results From Subgroup Analysis Based on Body Mass Index and Age From the Phase 3 ASCLEPIOS I/II Trials; P6.011. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
16. Freeman J, Delgado S, Alvarez E et al. Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials; P9.006. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
17. Delegado S, Alvarez E, Delgado S et al. Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials; P036. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
18. Akgün IK, Schulze-Topphoff U, Shuh K et al. A Prospective Data Collection to Evaluate Utility and Added Value of Serum NfL in Multiple Sclerosis – First Interim Insights from NeofiLos; P033. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
19. Sotirchos ES, Hu C, Smith MD et al. Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis. Neurology. 2023; 101(23): e2448-e2453. http://doi.org/10.1212/WNL.0000000000207957.
2.Oset M, Domowicz M, Wildner P et al. Predictive value of brain atrophy, serum biomarkers and information processing speed for early disease progression in multiple sclerosis. Front Neurol. 2023; 14: 1223220. http://doi.org/10.3389/fneur.2023.1223220.
3. Abdelhak A, Petermeier F, Benkert P et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 2023; 22(9): 826-33. http://doi.org/10.1016/S1474-4422(23)00210-7.
4. Monreal E, Fernández-Velasco JI, García-Sánchez MI et al. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs. JAMA Neurol. 2023; 80(4): 397-403. http://doi.org/10.1001/jamaneurol.2023.0010.
5.Arroyo Pereiro P, Muñoz-Vendrell A, León Moreno I et al. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort. J Neurol. 2024; 271(4): 1599-609. .
6. Bar-Or A, Thanei GA, Harp C et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023; 93: 104662. http://doi.org/10.1016/j.ebiom.2023.104662.
7.Fissolo N, Benkert P, Sastre-Garriga J et al. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2024; 95(5): 410-8. http://doi.org/10.1136/jnnp-2023-332251.
8. Williams T, Zetterberg H, Chataway J. Neurofilaments in progressive multiple sclerosis: a systematic review. J Neurol. 2021; 268(9): 3212-22. http://doi.org/10.1007/s00415-020-09917-x.
9. van Dam M, de Jong BA, Willemse EAJ et al. A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort. J Neurol. 2023; 270(8): 3851-61. http://doi.org/10.1007/s00415-023-11676-4.
10. Valentino P, Malucchi S, Bava CI et al. Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients. Mult Scler Relat Disord. 2023; 77: 104893. http://doi.org/10.1016/j.msard.2023.104893.
11. Oh U, Woolbright E, Lehner-Gulotta D et al. Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet. Mult Scler Relat Disord. 2023; 73: 104670. http://doi.org/10.1016/j.msard.2023.104670.
12. Kuhle J, Kappos L, Cross AH et al. Baseline serum neurofilament light levels have prognostic value for on-study MRI activity: Results from ASCLEPIOS trials; P0033. Zaprezentowano podczas kongresu ACTRIMS-ECTRIMS 11–13.09.2020 r.
13. Prado G, Kappos L, Cross AH et al. Ofatumumab Reduces Clinical and Radiological Activity in People With Recently Diagnosed Treatment-Naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels; P9.008. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
14. Leist T, Hauser S, Derfuss T et al. Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With\ Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials; P032. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
15. Cross A, Ziemssen T, Arnold D T et al. Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients With Relapsing Multiple Sclerosis: Results From Subgroup Analysis Based on Body Mass Index and Age From the Phase 3 ASCLEPIOS I/II Trials; P6.011. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
16. Freeman J, Delgado S, Alvarez E et al. Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials; P9.006. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
17. Delegado S, Alvarez E, Delgado S et al. Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials; P036. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
18. Akgün IK, Schulze-Topphoff U, Shuh K et al. A Prospective Data Collection to Evaluate Utility and Added Value of Serum NfL in Multiple Sclerosis – First Interim Insights from NeofiLos; P033. Zaprezentowano podczas kongresu ACTRIMS 29.02–2.03.2024.
19. Sotirchos ES, Hu C, Smith MD et al. Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis. Neurology. 2023; 101(23): e2448-e2453. http://doi.org/10.1212/WNL.0000000000207957.